ATE496901T1 - Cannabinoidderivate, verfahren zu deren herstellung und deren verwendung - Google Patents
Cannabinoidderivate, verfahren zu deren herstellung und deren verwendungInfo
- Publication number
- ATE496901T1 ATE496901T1 AT04752828T AT04752828T ATE496901T1 AT E496901 T1 ATE496901 T1 AT E496901T1 AT 04752828 T AT04752828 T AT 04752828T AT 04752828 T AT04752828 T AT 04752828T AT E496901 T1 ATE496901 T1 AT E496901T1
- Authority
- AT
- Austria
- Prior art keywords
- production
- tetrahydrocannabinol
- delta
- cannabinoid derivatives
- cannabinoid
- Prior art date
Links
- 229930003827 cannabinoid Natural products 0.000 title abstract 2
- 239000003557 cannabinoid Substances 0.000 title abstract 2
- 102000012234 Cannabinoid receptor type 1 Human genes 0.000 abstract 4
- 108050002726 Cannabinoid receptor type 1 Proteins 0.000 abstract 4
- 102000008906 Cannabinoid receptor type 2 Human genes 0.000 abstract 4
- 108050000860 Cannabinoid receptor type 2 Proteins 0.000 abstract 4
- XXGMIHXASFDFSM-UHFFFAOYSA-N Delta9-tetrahydrocannabinol Natural products CCCCCc1cc2OC(C)(C)C3CCC(=CC3c2c(O)c1O)C XXGMIHXASFDFSM-UHFFFAOYSA-N 0.000 abstract 1
- CYQFCXCEBYINGO-UHFFFAOYSA-N THC Natural products C1=C(C)CCC2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3C21 CYQFCXCEBYINGO-UHFFFAOYSA-N 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 abstract 1
- HCAWPGARWVBULJ-IAGOWNOFSA-N delta8-THC Chemical class C1C(C)=CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 HCAWPGARWVBULJ-IAGOWNOFSA-N 0.000 abstract 1
- 229960004242 dronabinol Drugs 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/78—Ring systems having three or more relevant rings
- C07D311/80—Dibenzopyrans; Hydrogenated dibenzopyrans
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Virology (AREA)
- Rheumatology (AREA)
- Psychology (AREA)
- AIDS & HIV (AREA)
- Communicable Diseases (AREA)
- Ophthalmology & Optometry (AREA)
- Physical Education & Sports Medicine (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrane Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US47231603P | 2003-05-20 | 2003-05-20 | |
| PCT/US2004/015885 WO2004113320A1 (en) | 2003-05-20 | 2004-05-20 | Cannabinoid derivatives, methods of making, and use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE496901T1 true ATE496901T1 (de) | 2011-02-15 |
Family
ID=33539041
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT04752828T ATE496901T1 (de) | 2003-05-20 | 2004-05-20 | Cannabinoidderivate, verfahren zu deren herstellung und deren verwendung |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US7169942B2 (enExample) |
| EP (1) | EP1633733B1 (enExample) |
| JP (1) | JP2007501279A (enExample) |
| CN (1) | CN1809552A (enExample) |
| AT (1) | ATE496901T1 (enExample) |
| AU (1) | AU2004249669B2 (enExample) |
| CA (1) | CA2526103A1 (enExample) |
| DE (1) | DE602004031221D1 (enExample) |
| DK (1) | DK1633733T3 (enExample) |
| WO (1) | WO2004113320A1 (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005093052A1 (en) * | 2004-03-26 | 2005-10-06 | Fuji Photo Film Co., Ltd. | Method for selectively separating and purifying rna and method for separating and purifying nucleic acid |
| USRE46558E1 (en) | 2005-04-28 | 2017-09-26 | Paloma Pharmaceuticals, Inc. | Compositions and methods to treat diseases characterized by cellular proliferation and angiogenesis |
| US20060257337A1 (en) * | 2005-04-28 | 2006-11-16 | David Sherris | Compositions and methods to treat skin diseases characterized by cellular proliferation and angiogenesis |
| AU2006297300B2 (en) * | 2005-09-29 | 2012-05-10 | Albany Molecular Research, Inc. | Process for production of delta-9-tetrahydrocannabinol |
| DE102005062098A1 (de) * | 2005-12-22 | 2007-06-28 | Merck Patent Gmbh | Oxaphenanthren-Derivate |
| JP2009528381A (ja) * | 2006-02-28 | 2009-08-06 | パロマ ファーマシューティカルズ，インク． | 細胞増殖および血管新生を特徴とする疾患を治療する組成物および方法 |
| WO2008109027A2 (en) | 2007-03-02 | 2008-09-12 | University Of Tennessee Research Foundation, The | Tri-aryl/heteroaroaromatic cannabinoids and use thereof |
| AU2009228303B2 (en) * | 2008-03-25 | 2015-08-13 | Paloma Pharmaceuticals, Inc. | Methods of treating fibrotic disorders |
| US8022078B2 (en) | 2008-05-19 | 2011-09-20 | University Of Tennessee Research Foundation | Pyrimidine classical cannabinoid compounds and related methods of use |
| CA2724697A1 (en) * | 2008-05-19 | 2009-11-26 | University Of Tennessee Research Foundation, The | Pyridine classical cannabinoid compounds and related methods of use |
| US8389534B2 (en) * | 2008-05-19 | 2013-03-05 | The University Of Tennessee Research Foundation | Pyrimidine non-classical cannabinoid compounds and related methods of use |
| US8476439B2 (en) | 2008-05-19 | 2013-07-02 | The University Of Tennessee Research Foundation | Pyridine classical cannabinoid compounds and related methods of use |
| CA2724737A1 (en) * | 2008-05-19 | 2009-11-26 | The University Of Tennessee Research Foundation | Pyrimidine non-classical cannabinoid compounds and related methods of use |
| US8349876B2 (en) * | 2008-05-19 | 2013-01-08 | The University Of Tennesee Research Foundation | Pyridine non-classical cannabinoid compounds and related methods of use |
| US8158654B2 (en) | 2008-05-19 | 2012-04-17 | The University Of Tennessee Research Foundation | Pyridine non-classical cannabinoid compounds and related methods of use |
| EP2309858A4 (en) | 2008-07-31 | 2011-09-14 | Dekel Pharmaceuticals Ltd | COMPOSITIONS AND METHOD FOR THE TREATMENT OF INFLAMMATORY DISEASES |
| WO2012112791A1 (en) | 2011-02-16 | 2012-08-23 | Paloma Pharmaceuticals, Inc. | Radiation countermeasure agents |
| CN103110582A (zh) * | 2013-03-04 | 2013-05-22 | 上海医药工业研究院 | 大麻酚类化合物微乳剂及其制备方法 |
| CA2952934A1 (en) | 2014-06-26 | 2015-12-30 | Island Breeze Systems Ca, Llc | Mdi related products and methods of use |
| US20170008869A1 (en) * | 2015-07-10 | 2017-01-12 | Noramco, Inc. | Process for the production of cannabidiol and delta-9-tetrahydrocannabinol |
| IL248149B (en) * | 2016-09-29 | 2020-03-31 | Garti Nissim | Formulations of dilutable cannabinoids and processes for their preparation |
| US10239808B1 (en) | 2016-12-07 | 2019-03-26 | Canopy Holdings, LLC | Cannabis extracts |
| US20180169061A1 (en) * | 2016-12-15 | 2018-06-21 | Ascent Pharmaceuticals, Inc. | Non-aqueous delta9-tetrahydrocannabinol oral liquid formulations |
| EP3672587A4 (en) | 2017-08-27 | 2021-05-19 | Rhodes Technologies | PHARMACEUTICAL COMPOSITIONS INTENDED FOR THE TREATMENT OF OPHTHALMIC DISORDERS |
| EP3745884A1 (en) | 2018-01-31 | 2020-12-09 | Canopy Holdings, Llc | Hemp powder |
| KR102880573B1 (ko) * | 2018-08-20 | 2025-11-04 | 베서, 파마 엘엘씨 | 칸나비노이드의 생성 공정 |
| US11040932B2 (en) | 2018-10-10 | 2021-06-22 | Treehouse Biotech, Inc. | Synthesis of cannabigerol |
| CN110269839A (zh) * | 2019-06-15 | 2019-09-24 | 云南飞久逍科技有限公司 | 一种大麻二酚cbd及其纳米乳在荨麻疹或/和鼻炎制剂中的应用 |
| CN114727960A (zh) * | 2019-10-03 | 2022-07-08 | 耶路撒冷希伯来大学伊森姆研究发展有限公司 | 数个脂质体大麻素及其用途 |
| EP4054335A4 (en) | 2019-11-08 | 2023-09-27 | Vella Bioscience, Inc. | Peripherally acting cannabidiol(cbd)-containing compositions and uses thereof for enhancing female sexual function or treating female sexual disorders |
| US12029718B2 (en) | 2021-11-09 | 2024-07-09 | Cct Sciences, Llc | Process for production of essentially pure delta-9-tetrahydrocannabinol |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3941782A (en) | 1972-04-27 | 1976-03-02 | Sharps Associates | Heterocyclic esters of benzopyrans |
| US3915996A (en) * | 1972-10-16 | 1975-10-28 | Abbott Lab | Process for making benzopyrans |
| US3901926A (en) | 1973-04-02 | 1975-08-26 | Abbott Lab | Alkylphenyl benzopyrans |
| DE4100441A1 (de) * | 1991-01-09 | 1992-07-16 | Mack Chem Pharm | Verfahren zur herstellung von 6,12-dihydro-6-hydroxy-cannabidiol und dessen verwendung zur herstellung von trans-delta-9-tetrahydrocannabinol |
| US5596106A (en) | 1994-07-15 | 1997-01-21 | Eli Lilly And Company | Cannabinoid receptor antagonists |
| CA2278307A1 (en) | 1997-01-21 | 1998-07-23 | Siegfried Benjamin Christensen Iv | Novel cannabinoid receptor modulators |
| FR2758723B1 (fr) | 1997-01-28 | 1999-04-23 | Sanofi Sa | Utilisation des antagonistes des recepteurs aux cannabinoides centraux pour la preparation de medicaments |
| DE19706903A1 (de) | 1997-02-21 | 1998-08-27 | Bayer Ag | Verwendung von bekannten Agonisten des zentralen Cannabinoid-Rezeptors CB 1 |
| EP0979228A4 (en) | 1997-03-18 | 2000-05-03 | Smithkline Beecham Corp | CANNABINOID RECEPTOR AGONISTS |
| US5939429A (en) | 1997-09-30 | 1999-08-17 | Virginia Commonwealth University | Cardiovascular uses of cannabinoid compounds |
| ATE247097T1 (de) * | 1998-05-04 | 2003-08-15 | Univ Connecticut | Analgetische und immunomodulierende cannabinoiden |
| US6563009B1 (en) | 1999-07-12 | 2003-05-13 | Virginia Commonwealth University | Vasodilator cannabinoid analogs |
| FR2799124B1 (fr) | 1999-10-01 | 2004-08-13 | Sanofi Synthelabo | Utilisation des antagonistes des recepteurs aux cannabinoides centraux pour la preparation de medicaments |
| IL132661A (en) | 1999-10-31 | 2008-11-26 | Raphael Mechoulam | Agonists specific for peripheral cannabinoid receptors |
| FR2804604B1 (fr) | 2000-02-09 | 2005-05-27 | Sanofi Synthelabo | Utilisation d'un antagoniste des recepteurs aux cannabinoides centraux pour la preparation de medicaments utiles pour faciliter l'arret de la consommation de tabac |
| EP1254115A2 (en) | 2000-02-11 | 2002-11-06 | Bristol-Myers Squibb Company | Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators for treating respiratory and non-respiratory diseases |
| US20040039048A1 (en) | 2000-02-11 | 2004-02-26 | Manuel Guzman Pastor | Therapy with cannabinoid compounds for the treatment of brain tumors |
| US6448288B1 (en) | 2000-05-17 | 2002-09-10 | University Of Massachusetts | Cannabinoid drugs |
| EP1299374B1 (en) * | 2000-06-22 | 2006-12-27 | Pharmos Corporation | Novel non-psychotropic cannabinoids |
| US7507767B2 (en) | 2001-02-08 | 2009-03-24 | Schering Corporation | Cannabinoid receptor ligands |
| US7067539B2 (en) | 2001-02-08 | 2006-06-27 | Schering Corporation | Cannabinoid receptor ligands |
| US6509367B1 (en) | 2001-09-22 | 2003-01-21 | Virginia Commonwealth University | Pyrazole cannabinoid agonist and antagonists |
| CA2466440A1 (en) | 2001-11-14 | 2003-05-22 | Schering Corporation | Cannabinoid receptor ligands |
| AU2003243637A1 (en) | 2002-06-19 | 2004-01-06 | Schering Corporation | Cannabinoid receptor agonists |
| JP2006506366A (ja) | 2002-10-18 | 2006-02-23 | ファイザー・プロダクツ・インク | カンナビノイド受容体リガンドおよびその使用方法 |
-
2004
- 2004-05-20 EP EP04752828A patent/EP1633733B1/en not_active Expired - Lifetime
- 2004-05-20 AT AT04752828T patent/ATE496901T1/de not_active IP Right Cessation
- 2004-05-20 CA CA002526103A patent/CA2526103A1/en not_active Abandoned
- 2004-05-20 AU AU2004249669A patent/AU2004249669B2/en not_active Ceased
- 2004-05-20 JP JP2006533257A patent/JP2007501279A/ja active Pending
- 2004-05-20 DK DK04752828.6T patent/DK1633733T3/da active
- 2004-05-20 WO PCT/US2004/015885 patent/WO2004113320A1/en not_active Ceased
- 2004-05-20 US US10/850,588 patent/US7169942B2/en not_active Expired - Fee Related
- 2004-05-20 CN CNA2004800174008A patent/CN1809552A/zh active Pending
- 2004-05-20 DE DE602004031221T patent/DE602004031221D1/de not_active Expired - Lifetime
-
2007
- 2007-01-26 US US11/698,665 patent/US20070167514A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| DE602004031221D1 (de) | 2011-03-10 |
| US20040242593A1 (en) | 2004-12-02 |
| EP1633733A1 (en) | 2006-03-15 |
| AU2004249669A1 (en) | 2004-12-29 |
| EP1633733B1 (en) | 2011-01-26 |
| DK1633733T3 (da) | 2011-05-16 |
| AU2004249669B2 (en) | 2008-05-22 |
| CA2526103A1 (en) | 2004-12-29 |
| US20070167514A1 (en) | 2007-07-19 |
| EP1633733A4 (en) | 2007-02-28 |
| US7169942B2 (en) | 2007-01-30 |
| WO2004113320A1 (en) | 2004-12-29 |
| CN1809552A (zh) | 2006-07-26 |
| JP2007501279A (ja) | 2007-01-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE496901T1 (de) | Cannabinoidderivate, verfahren zu deren herstellung und deren verwendung | |
| NO20010446L (no) | Substituert anilidforbindelser og metoder | |
| DE60120494D1 (de) | Substituieten triazoldiamin derivaten und ihre verwendung als kinase inhibitoren | |
| DE69728585D1 (de) | Mittel gegen Juckreiz | |
| ATE338565T1 (de) | Verwendung eines antagonisten antikörpers gegen den entzündungsmediator oncostatin m (osm) | |
| BRPI0413563A (pt) | compostos e composições como inibidores de atividade do receptor de quìnase de tirosina | |
| DE69422191D1 (de) | A1 adenosin rezeptor agonisten und antagonisten | |
| BR0007595A (pt) | 4-(heterociclisulfonamido)-5-metóxi-6-(2-metoxifenó xi)-2-fenil-ou piridilpirimidinas como antagonistas de receptor de endotelina | |
| ATE272631T1 (de) | Neue hydroxyindole, deren verwendung als inhibitoren der phosphodiesterase 4 und verfahren zu deren herstellung | |
| AUPO755097A0 (en) | Receptor agonist and antagonist | |
| BR0015962A (pt) | Compostos tendo ligações multiplas que são agonistas de receptor adrenérgico (beta)2 úteis no tratamento e prevenção de doenças respiratórias | |
| BR9914526A (pt) | Derivados de adenina | |
| PT1218352E (pt) | Novos derivados de benzimidazolona tendo receptores com afinidade mista para os receptores de serotonina e dopamina | |
| DE69835225D1 (de) | Methode zur behandlung von durch glycocorticoidstörungen verursachten psychosen | |
| TR199900090A2 (xx) | Benzos�lfon t�revleri | |
| ATE234322T1 (de) | A1 adenosin rezeptor agonisten und antagonisten | |
| DE60103384D1 (de) | Metabotrope glutamatrezeptorantagonisten zur behandlung von toleranz und abhängigkeit | |
| ATE239823T1 (de) | Verffahren und vorrichtung zur steuerung der papiereigenschaften | |
| AU5614198A (en) | Isoquinolinamine and phthalazinamine derivatives which interact with crf receptors | |
| DE60103856D1 (de) | Thiazolopyrimidine und ihre verwendung als modulatoren der chemokin-rezeptor-aktivität | |
| BR0307903A (pt) | derivados de arilsulfona | |
| EP1305023A4 (en) | USE OF ADENOSINE A1 RECEPTOR SELECTIVE ALLOSTERIC AGONISTS, ANTAGONISTS AND AMPLIFIERS TO MANIPULATE ANGIOGENESIS | |
| BRPI0409730A (pt) | tratamento da incontinência | |
| ATE519762T1 (de) | Benzazepinverbindungen mit affinität für den dopamin-d3-rezeptor und deren verwendung | |
| DE69633131D1 (de) | Rezeptor des y-y5 neuropeptids |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |